A single intravenous infusion of Lilly's investigational base editor VERVE‑102 produced dose-dependent reductions in PCSK9 of up to 88 per cent and LDL cholesterol of up to 62 per cent, with effects sustained for up to 18 months. …
Single infusion of Lilly gene editing cuts cholesterol with the company planning long-term study
May 27, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Territory partnership backs digital health push for diabetes, kidney and heart care
July 9, 2026 - - Latest News -
It might make sense to follow the process, mostly, but no need to keep patients waiting
July 9, 2026 - - Latest News -
Illumina taps medtech leader to head Australia and New Zealand operations
July 8, 2026 - - Latest News -
PYC Therapeutics names Thomas Ulmer as new chief financial officer
July 8, 2026 - - Australian Biotech -
In a perfect world, the minister would not be in this position, and he might question the timeline
July 8, 2026 - - Latest News -
Aegros completes Australia’s second large scale plasma fractionation plant
July 8, 2026 - - Latest News -
'But I've said it's really important that these two drugs stay on the PBS'
July 7, 2026 - - Latest News